Immunotherapeutic Advances in Alzheimer’s Disease: The Convergence of Vaccinology and Nanoscience

Immunotherapeutic Advances in Alzheimer’s Disease: The Convergence of Vaccinology and Nanoscience Hanish Singh Jayasingh Chellammal https://orcid.org/0000-0001-9110-606X Ashok Kumar Janakiraman https://orcid.org/0000-0002-9670-8323 Dhani Ramachandran Ronald Darwin Chellappan Mohamed Saleem Thattakudian Sheikuduman Madhan Kumar Soutallu Janakiram https://orcid.org/0000-0002-1395-6453 Hemanth Kumar Boyina Mohamed Shabi Mohamed Abdul Kader https://orcid.org/0000-0003-0974-3938 Senthil Kumar Kannan Raju Sugavasi Abstract:

Amyloid-beta plaques and neurofibrillary tangles promote neuronal dysfunction and cognitive loss, the hallmarks of Alzheimer's disease (AD), a serious global health concern. Current medications offer only symptomatic alleviation, emphasizing the critical need for disease-- modifying therapy. This study was performed using MeSH term search by using keywords, like “Alzheimer’s Disease”, “AD”, “Vaccines”, “Nanoformulations”, “Amyloid-Beta (Aβ) Vaccines”, “lecanemab”, “Tau protein Vaccines”, “AADvac1”, “Clinical trials”. The development of vaccines and methods based on nanotechnology is the primary focal point of this review, which explores immunotherapeutic approaches. Active and passive immunization are used in the development of AD vaccines to target tau and amyloid-beta pathology. While passive immunization involves the direct delivery of pre-formed antibodies, active immunization aims to stimulate the patient's own immune system to produce antibodies in response to the antigen. The necessity for effective drug delivery across the blood-brain barrier (BBB), safety issues, and inconsistent efficacy are some of the difficulties facing vaccine delivery strategies. Nanotechnology can overcome the drawbacks of traditional treatments by providing novel approaches for gene therapy, RNA-based interventions, and targeted medication administration. Immunization approaches offer multiple benefits, including regulated and targeted antigen release, as well as stabilizing the vaccine antigens. Therapeutic drugs can be delivered across the BBB, and genes linked to AD can be modulated by nanoparticles and liposomes that resemble exosomes. Current developments, including the incorporation of short Aβ epitopes, liposomal formulations, conformational mimotopes, and virus-- like particles (VLPs), have markedly enhanced vaccine tolerability. Effective AD treatments depend on combination medications, individualized approaches, and ongoing research into crossing the BBB and improving the safety and effectiveness of vaccines.
05 22 2026 LiveAll1 1 10.2174/BSP_crossmark_policy eurekaselect.com true Peer Reviewed Double blind Checked with iThenticate 2025-05-16 2025-08-18 2025-09-04 2026-05-22 10.2174/0115672050415433251106050120 https://www.eurekaselect.com/254400/article https://www.eurekaselect.com/254400/article https://www.eurekaselect.com/article/download?doi=10.2174/0115672050415433251106050120 https://www.eurekaselect.com/article/download?doi=10.2174/0115672050415433251106050120 https://www.eurekaselect.com/article/download?doi=10.2174/0115672050415433251106050120 https://www.eurekaselect.com/article/download?doi=10.2174/0115672050415433251106050120 https://www.eurekaselect.com/article/download?doi=10.2174/0115672050415433251106050120 https://www.eurekaselect.com/article/download?doi=10.2174/0115672050415433251106050120 https://www.eurekaselect.com/254400/article